Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">PET Imaging of Very Late Antigen-4 in Melanoma: Comparison of <sup>68</sup>Ga- and <sup>64</sup>Cu-Labeled NODAGA and CB-TE1A1P-LLP2A Conjugates</title><author><name sortKey="Beaino, Wissam" sort="Beaino, Wissam" uniqKey="Beaino W" first="Wissam" last="Beaino">Wissam Beaino</name><affiliation><nlm:aff id="A1">Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania</nlm:aff></affiliation></author><author><name sortKey="Anderson, Carolyn J" sort="Anderson, Carolyn J" uniqKey="Anderson C" first="Carolyn J." last="Anderson">Carolyn J. Anderson</name><affiliation><nlm:aff id="A1">Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania</nlm:aff></affiliation><affiliation><nlm:aff id="A2">Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania</nlm:aff></affiliation><affiliation><nlm:aff id="A3">Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">25256059</idno><idno type="pmc">4277817</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277817</idno><idno type="RBID">PMC:4277817</idno><idno type="doi">10.2967/jnumed.114.144881</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">000D51</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000D51</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">PET Imaging of Very Late Antigen-4 in Melanoma: Comparison of <sup>68</sup>Ga- and <sup>64</sup>Cu-Labeled NODAGA and CB-TE1A1P-LLP2A Conjugates</title><author><name sortKey="Beaino, Wissam" sort="Beaino, Wissam" uniqKey="Beaino W" first="Wissam" last="Beaino">Wissam Beaino</name><affiliation><nlm:aff id="A1">Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania</nlm:aff></affiliation></author><author><name sortKey="Anderson, Carolyn J" sort="Anderson, Carolyn J" uniqKey="Anderson C" first="Carolyn J." last="Anderson">Carolyn J. Anderson</name><affiliation><nlm:aff id="A1">Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania</nlm:aff></affiliation><affiliation><nlm:aff id="A2">Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania</nlm:aff></affiliation><affiliation><nlm:aff id="A3">Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania</nlm:aff></affiliation></author></analytic><series><title level="j">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</title><idno type="ISSN">0161-5505</idno><idno type="eISSN">1535-5667</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">Melanoma is a malignant tumor derived from epidermal melanocytes, and it is known for its aggressiveness, therapeutic resistance, and predisposition for late metastasis. Very late antigen-4 (VLA-4; also called integrin α<sub>4</sub>β<sub>1</sub>) is a transmembrane noncovalent heterodimer overexpressed in melanoma tumors that plays an important role in tumor growth, angiogenesis, and metastasis by promoting adhesion and migration of cancer cells. In this study, we evaluated 2 conjugates of a high-affinity VLA-4 peptidomimetic ligand, LLP2A, for PET/CT imaging in a subcutaneous and metastatic melanoma tumor.</p><sec id="S1"><title>Methods</title><p id="P2">LLP2A was conjugated to 1,4,8,11-tetraazacyclotetradecane-1-(methane phosphonic acid)-8-(methane carboxylic acid) (CB-TE1A1P) and 2-(4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl)pentanedioic acid (NODAGA) chelators for <sup>68</sup>Ga and <sup>64</sup>Cu labeling. The conjugates were synthesized by solid-phase peptide synthesis, purified by reversed-phase high-performance liquid chromatography, and verified by liquid chromatography mass spectrometry. Saturation and competitive binding assays with B16F10 melanoma cells determined the affinity of the compounds for VLA-4. The biodistributions of the LLP2A conjugates were evaluated in murine B16F10 subcutaneous tumor–bearing C57BL/6 mice. Melanoma metastasis was induced by intracardiac injection of B16F10 cells. PET/CT imaging was performed at 2, 4, and 24 h after injection for the <sup>64</sup>Cu tracers and 1 h after injection for the <sup>68</sup>Ga tracer.</p></sec><sec id="S2"><title>Results</title><p id="P3"><sup>64</sup>Cu-labeled CB-TE1A1P-PEG<sub>4</sub>-LLP2A and NODAGA-PEG<sub>4</sub>-LLP2A showed high affinity to VLA-4, with a comparable dissociation constant (0.28 vs. 0.23 nM) and receptor concentration (296 vs. 243 fmol/mg). The tumor uptake at 2 h after injection was comparable for the 2 probes, but <sup>64</sup>Cu-CB-TE1A1P-PEG<sub>4</sub>-LLP2A trended toward higher uptake than <sup>64</sup>Cu-NODAGA-PEG<sub>4</sub>-LLP2A (16.9 ± 2.2 vs. 13.4 ± 1.7 percentage injected dose per gram, <italic>P</italic> = 0.07). Tumor-to-muscle and tumor-to-blood ratios from biodistribution and PET/CT images were significantly higher for <sup>64</sup>Cu-CB-TE1A1P-PEG<sub>4</sub>-LLP2A than <sup>64</sup>Cu-NODAGA-PEG<sub>4</sub>-LLP2A (all <italic>P</italic> values < 0.05). PET/CT imaging of metastatic melanoma with <sup>68</sup>Ga-NODAGA-PEG<sub>4</sub>-LLP2A and <sup>64</sup>Cu-NODAGA-PEG<sub>4</sub>-LLP2A showed high uptake of the probes at the site of metastasis, correlating with the bioluminescence imaging of the tumor.</p></sec><sec id="S3"><title>Conclusion</title><p id="P4">These data demonstrate that <sup>64</sup>Cu-labeled CB-TE1A1P/NODAGA LLP2A conjugates and <sup>68</sup>Ga-labeled NODAGA-LLP2A are excellent imaging agents for melanoma and potentially other VLA-4–positive tumors. <sup>64</sup>Cu-CB-TE1A1P-PEG<sub>4</sub>-LLP2A had the most optimal tumor–to–nontarget tissue ratios for translation into humans as a PET imaging agent for melanoma.</p></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">0217410</journal-id><journal-id journal-id-type="pubmed-jr-id">5045</journal-id><journal-id journal-id-type="nlm-ta">J Nucl Med</journal-id><journal-id journal-id-type="iso-abbrev">J. Nucl. Med.</journal-id><journal-title-group><journal-title>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</journal-title></journal-title-group><issn pub-type="ppub">0161-5505</issn><issn pub-type="epub">1535-5667</issn></journal-meta><article-meta><article-id pub-id-type="pmid">25256059</article-id><article-id pub-id-type="pmc">4277817</article-id><article-id pub-id-type="doi">10.2967/jnumed.114.144881</article-id><article-id pub-id-type="manuscript">NIHMS646693</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>PET Imaging of Very Late Antigen-4 in Melanoma: Comparison of <sup>68</sup>Ga- and <sup>64</sup>Cu-Labeled NODAGA and CB-TE1A1P-LLP2A Conjugates</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Beaino</surname><given-names>Wissam</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Anderson</surname><given-names>Carolyn J.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania</aff><aff id="A2"><label>2</label>Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania</aff><aff id="A3"><label>3</label>Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania</aff><author-notes><corresp id="FN1">For correspondence or reprints contact: Carolyn J. Anderson, Department of Radiology, University of Pittsburgh, 100 Technology Dr., Suite 452, Pittsburgh, PA 15219. <email>andersoncj@upmc.edu</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>5</day><month>12</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>25</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="ppub"><month>11</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>11</month><year>2015</year></pub-date><volume>55</volume><issue>11</issue><fpage>1856</fpage><lpage>1863</lpage><pmc-comment>elocation-id from pubmed: 10.2967/jnumed.114.144881</pmc-comment>
<permissions><copyright-statement>COPYRIGHT © 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.</copyright-statement><copyright-year>2014</copyright-year></permissions><abstract><p id="P1">Melanoma is a malignant tumor derived from epidermal melanocytes, and it is known for its aggressiveness, therapeutic resistance, and predisposition for late metastasis. Very late antigen-4 (VLA-4; also called integrin α<sub>4</sub>β<sub>1</sub>) is a transmembrane noncovalent heterodimer overexpressed in melanoma tumors that plays an important role in tumor growth, angiogenesis, and metastasis by promoting adhesion and migration of cancer cells. In this study, we evaluated 2 conjugates of a high-affinity VLA-4 peptidomimetic ligand, LLP2A, for PET/CT imaging in a subcutaneous and metastatic melanoma tumor.</p><sec id="S1"><title>Methods</title><p id="P2">LLP2A was conjugated to 1,4,8,11-tetraazacyclotetradecane-1-(methane phosphonic acid)-8-(methane carboxylic acid) (CB-TE1A1P) and 2-(4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl)pentanedioic acid (NODAGA) chelators for <sup>68</sup>Ga and <sup>64</sup>Cu labeling. The conjugates were synthesized by solid-phase peptide synthesis, purified by reversed-phase high-performance liquid chromatography, and verified by liquid chromatography mass spectrometry. Saturation and competitive binding assays with B16F10 melanoma cells determined the affinity of the compounds for VLA-4. The biodistributions of the LLP2A conjugates were evaluated in murine B16F10 subcutaneous tumor–bearing C57BL/6 mice. Melanoma metastasis was induced by intracardiac injection of B16F10 cells. PET/CT imaging was performed at 2, 4, and 24 h after injection for the <sup>64</sup>Cu tracers and 1 h after injection for the <sup>68</sup>Ga tracer.</p></sec><sec id="S2"><title>Results</title><p id="P3"><sup>64</sup>Cu-labeled CB-TE1A1P-PEG<sub>4</sub>-LLP2A and NODAGA-PEG<sub>4</sub>-LLP2A showed high affinity to VLA-4, with a comparable dissociation constant (0.28 vs. 0.23 nM) and receptor concentration (296 vs. 243 fmol/mg). The tumor uptake at 2 h after injection was comparable for the 2 probes, but <sup>64</sup>Cu-CB-TE1A1P-PEG<sub>4</sub>-LLP2A trended toward higher uptake than <sup>64</sup>Cu-NODAGA-PEG<sub>4</sub>-LLP2A (16.9 ± 2.2 vs. 13.4 ± 1.7 percentage injected dose per gram, <italic>P</italic> = 0.07). Tumor-to-muscle and tumor-to-blood ratios from biodistribution and PET/CT images were significantly higher for <sup>64</sup>Cu-CB-TE1A1P-PEG<sub>4</sub>-LLP2A than <sup>64</sup>Cu-NODAGA-PEG<sub>4</sub>-LLP2A (all <italic>P</italic> values < 0.05). PET/CT imaging of metastatic melanoma with <sup>68</sup>Ga-NODAGA-PEG<sub>4</sub>-LLP2A and <sup>64</sup>Cu-NODAGA-PEG<sub>4</sub>-LLP2A showed high uptake of the probes at the site of metastasis, correlating with the bioluminescence imaging of the tumor.</p></sec><sec id="S3"><title>Conclusion</title><p id="P4">These data demonstrate that <sup>64</sup>Cu-labeled CB-TE1A1P/NODAGA LLP2A conjugates and <sup>68</sup>Ga-labeled NODAGA-LLP2A are excellent imaging agents for melanoma and potentially other VLA-4–positive tumors. <sup>64</sup>Cu-CB-TE1A1P-PEG<sub>4</sub>-LLP2A had the most optimal tumor–to–nontarget tissue ratios for translation into humans as a PET imaging agent for melanoma.</p></sec></abstract><kwd-group><kwd>LLP2A</kwd><kwd>melanoma</kwd><kwd>VLA-4</kwd><kwd>PET</kwd><kwd>metastasis</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D51 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000D51 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.38. |  |